NORDEA INVESTMENT MANAGEMENT AB
Institutional investor · Portfolio as of Q1 2019
Top Holdings1,373 positions
Johnson & Johnson | 8.7M | $1.2B | 2.5% | $113.77 | 0.00% | 1 qtr | First report 0 |
Apple Inc. | 5.8M | $1.1B | 2.3% | $45.22 | 0.00% | 1 qtr | First report 0 |
Microsoft Corp. | 8.9M | $1B | 2.2% | $110.12 | 0.00% | 1 qtr | First report 0 |
Cisco Systems, Inc. | 19.1M | $1B | 2.2% | $43.51 | 0.00% | 1 qtr | First report 0 |
Amgen Inc. | 4.7M | $894.7M | 1.9% | $151.37 | 0.00% | 1 qtr | First report 0 |
Medtronic PLC | 8.6M | $785.3M | 1.6% | $73.57 | 0.00% | 1 qtr | First report 0 |
Alphabet Inc. | 638,536 | $751.5M | 1.6% | $58.12 | 0.00% | 1 qtr | First report 0 |
COGNIZANT TECHNOLOGY SOLUTIO | 10.2M | $736.2M | 1.5% | $64.35 | 0.00% | 1 qtr | First report 0 |
ANTHEM INC | 2.5M | $715M | 1.5% | $258.46 | 0.00% | 1 qtr | First report 0 |
PFIZER INC | 16.5M | $699.6M | 1.5% | $28.06 | 0.00% | 1 qtr | First report 0 |
COMCAST CORP NEW | 17.3M | $690.7M | 1.4% | $29.81 | 0.00% | 1 qtr | First report 0 |
Oracle Corp. | 12.8M | $685.1M | 1.4% | $48.13 | 0.00% | 1 qtr | First report 0 |
CVS HEALTH CORP | 12.4M | $670.2M | 1.4% | $42.32 | 0.00% | 1 qtr | First report 0 |
AT&T INC | 21.2M | $666.4M | 1.4% | $13.94 | 0.00% | 1 qtr | First report 0 |
VERIZON COMMUNICATIONS INC | 10.9M | $644.5M | 1.3% | $38.16 | 0.00% | 1 qtr | First report 0 |
CHUBB LIMITED | 4.5M | $629.4M | 1.3% | $124.67 | 0.00% | 1 qtr | First report 0 |
Merck & Co., Inc | 7.2M | $600.1M | 1.3% | $63.02 | 0.00% | 1 qtr | First report 0 |
| 9.9M | $595.3M | 1.2% | $32.09 | +87.13% | 1 qtr | First report 0 | |
BANK NOVA SCOTIA B C | 8.3M | $585.3M | 1.2% | $36.85 | 0.00% | 1 qtr | First report 0 |
ALIBABA GROUP HLDG LTD | 3.1M | $574.4M | 1.2% | $171.70 | 0.00% | 1 qtr | First report 0 |
NORDEA INVESTMENT MANAGEMENT AB manages $48B across 1373 positions as of Q1 2019. Top holdings: JNJ (2.5%), AAPL (2.3%), MSFT (2.2%). Fund DNA: Steady Compounder. HoldingsIntel Score: 2/5.0.
First quarter we have for this fund: 1373 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $48.0B across 1373 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR